Residential radon exposure has been estimated to cause 7000 to 30000 deaths each year in the United States.' About one third of these deaths are due to residential exposure in excess of 4 pCi/L (the recommended action level for radon mitigation in the United States) and thus are potentially preventable. In 1986 the Environmental Protection Agency (EPA) and the Department of Health and Human Services recommended radon screening for most homes in the United States, and in 1992 the recommendation was revised to include a 2-step strategy for measuring residential radon: a short-term screening measurement followed by a confirmatory measurement if the screening measurement was 4 pCi/L or greater.23 However, in recent years, it has been suggested that testing and mitigation recommendations should be targeted to households in geographic areas with elevated radon levels.4 Some remain unconvinced that residential radon exposure represents a major threat to the US population.5
Because the costs of residential radon testing and remediation are high, examining various options for lowering the risk for individual and population exposure to radon is important.
At least 11 economic analyses of radon reduction programs have been reported." 46 
Methods
We developed a decision tree'5 that 
Note. Probabilities for decision and terminal nodes vary depending on location in decision tree and type of screening strategy.
FIGURE 1-Simplified decision tree presenting various options of radon testing and mitigation.
The analysis examined the lifetime costs and effects of these approaches to reducing exposure to radon and prevention of lung cancer in a stationary population of about 250 million people whose age structure reflected the 1990 US Census. The societal approach included all costs and benefits. To facilitate modeling and comparisons of differences among strategies, we assumed a 2-year period during which an intervention would occur and decisions and actions about radon testing and mitigation would be performed and implemented.
Costs
The costs are presented in 1993 dollars and include those associated with both the intervention (program, testing, and mitigation costs) and radon-related lung cancer deaths (direct medical costs and productivity losses from lung cancer morbidity and mortality). In order to convert future costs to 1993 dollars, they were discounted 4% per year.
The universal screening program cost used in this analysis was $18 776 000 (50% of the 5-year average of EPA funding of $18 000 000 along with $9 776 000 in nonfederal funds related to residential radon exposure) ( 
Age
From the first decade through the fourth decade of life, the cost-effectiveness estimates for the universal and targeted scenarios decrease, after which they progressively increase with increasing age (particularly after age 79). For the third through sixth decades of life, the cost-effectiveness estimates are less than $2 million to prevent a lung cancer death for the universal scenario and less still for the targeted scenario.
Sensitivity Analyses
For the universal scenario, increasing the probability ofretesting for the presence of elevated radon levels, the probability of mitigating, or the probability of successfully mitigating improved the cost-effectiveness estimates (Table 4 estimate, it did result in a large increase in the number of lung cancer deaths that could be prevented. However, in no case was more than a fraction of the theoretical number of preventable deaths achieved.
The results from the sensitivity analyses were generally similar for the modified universal scenario. The biggest departure was that decreases in the probability of retesting resulted in decreases in the cost-effectiveness estimate and in the number of lung cancer deaths that could be prevented. The choice of a discount rate can strongly influence costeffectiveness estimates; these estimates were $1.8 million for the universal scenario and $1.4 million for the targeted strategy at a 0% discount rate and $4.8 million for the universal scenario and $3.3 million for the targeted strategy at a 7% discount rate.
Incremental Cost-Effectiveness Analysis
Incremental costs increased as the radon threshold was lowered from 20 pCi/L to 2 pCi/L, and especially when the threshold was lowered from 4 pCi/L to 2 pCi/L (Table 5) .
Depending on the radon threshold, either the targeted or modified targeted scenario had the lowest total cost, and either the universal or modified universal scenario had the highest total cost. At 4 pCi/L, the incremental costs were $150 000 for moving from a targeted to a modified targeted scenario and $1.66 million for moving from a modified targeted to a modified universal scenario.
Discussion
The issue of radon testing and mitigation has been contentious owing to the potentially high costs that would be borne by homeowners and to the lingering controversy over the magnitude of the risks from residential radon exposure. Assuming that excessive exposure to radon elevates the risk of dying of lung cancer, how best to implement a radon testing and mitigation program becomes an important consideration.
The differences in cost-effectiveness among models raise the question of model superiority. The universal model using the best estimate of probabilities suggests that only about 4000 homes would be mitigated annually, whereas the modified universal model suggests that about 45 We explored three possibilities for focusing radon screening efforts: screening all homes vs screening homes in geographically defined high radon risk areas, screening homes of smokers vs those of nonsmokers, and screening homes of all age groups vs those of selected age groups. When best estimates of compliance are used, a geographical approach aimed at screening about one third of the country with predicted elevated radon levels produces more favorable costeffectiveness estimates than do universal approaches. In addition, targeted approaches prevent about 50% to 80% the number of predicted lung cancer deaths of comparable universal approaches, because the positive predictive value of the test is substantially improved in a setting where a higher prevalence of dwellings contain radon levels above a particular threshold.
Most lung cancer deaths from radon exposure occur among current and former smokers.'0 In a multiplicative model about 10% of radon-associated lung cancer deaths would occur among nonsmokers, while in a submultiplicative assumption about 30% of these deaths would be predicted to occur among nonsmokers.3' As a result, the costeffectiveness estimate for nonsmokers under a submultiplicative model is substantially lower than under a multiplicative model. Nevertheless, preventing lung cancer deaths among nonsmokers is still more expensive than preventing such deaths among smokers.
The age-specific analysis suggests that few lives would be saved (at increasingly high costs) from testing and mitigating radon from homes inhabited only by people more than 70 years of age because of the declining remaining lifetime risk for lung cancer among people of advanced age. Although partitioning the total housing stock according to the age distribution may have introduced some error into the analyses, it is unlikely to have affected the results in a significant way.
Using the Finnish radon distribution,
Castren suggested that cost-effectiveness decreased as the action level was raised but increased when estimates were based on a theoretical radon distribution.7 Both the EPA and the Department of Energy analyses produced a shallow U-shaped curve with the lowest cost-effectiveness ratios at 8 pCi/L and 10 pCi/L, respectively.""l Our analysis suggests that, depending on the scenario, either 4 or 8 pCi/L is a reasonable threshold.
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Sensitivity analyses show the large improvements in cost-effectiveness that could be achieved if adherence to existing recommendations were increased. Costeffectiveness can be improved by increasing the proportion of people who would retest their homes and mitigate if necessary. To prevent the maximum number of lung cancer deaths, compliance with all of the recommendations needs to be maximized. Similar conclusions were reached by Bierma.8 A number of methodological limitations must be borne in mind when evaluating these data. Because data for many of the variables were sparse, frequently dated, and of questionable generalizability, we often modeled data from national surveys. We also used probabilities for decision nodes that were based on probabilities for 4 pCi/L in estimating the cost-effectiveness estimates for other radon thresholds. Risk estimates were based on formulas developed from mining studies. Extrapolation of these data to the residential enviroument is uncertain.33 '34 Because the total lung cancer and all-cause mortality rates were disaggregated on the basis of summary relative risk and prevalence estimates, some error may have been introduced into the resulting estimates. The average radon exposures for each terminal node were also estimates. For example, for people who failed to mitigate sufficiently, we assigned (using data from the National Residential Radon Survey) the average level of radon exposure that was above the action threshold for the entire population that tested above that threshold. If favorable cost-effectiveness ratios. Furthermore, the present analysis did not attempt to examine the impact of construction guidelines for new homes. Our assumption that preventable lung cancer deaths would be equally spaced in time, starting at a certain age, is likely to have underestimated costeffectiveness estimates. In addition, the cost estimated for the targeted program was based on an intensive program in Washington, DC, and may have overestimated the true costs of an effective targeted program. However, an overestimation of these costs would have tended to narrow the differences in cost-effectiveness estimates between universal and targeted programs, making the findings of our analysis even more robust.
In conclusion, more cost-effective residential radon mitigation programs can be developed by focusing on geographically defined areas where the risk of exposure to elevated levels of radon is high. Our analysis shows that it is more cost-effective to prevent radon-associated lung cancer deaths among people who smoke; from a public health perspective, however, helping smokers to quit smoking is obviously more desirable. Smoking cessation programs are more costeffective.3739 Substantial improvements in compliance are needed to maximize the number of lung cancer deaths that can be prevented. Experience has shown that actual compliance with recommendations falls far short of expectations,21'22'40 and increasing compliance may prove a difficult task. Therefore, examination of regulatory and behavioral options is needed. In addition, our analysis underscores the need for more current data on most of the decision nodes that we modeled in our decision tree. Finally, new cost-effectiveness estimates may need to be developed when additional data from residential case-control studies of radon exposure and lung cancer become available. D Contributors E. S. Ford took the lead in performing the analyses and writing the paper. A. E. Kelly assisted with the analyses and the writing of the paper. S. M. Teutsch supervised data analysis and contributed to the writing ofthe paper. S. B. Thacker was instrumental in the conception ofthe paper and contributed to the writing of the paper. P. L. Garbe contributed to the writing of the paper. All authors are guarantors for the integrity of the research.
